J&J completes €300m Irish expansion, adding 200 jobs

By Ben Hargreaves contact

- Last updated on GMT

(Image: Getty/Filipefrazao)
(Image: Getty/Filipefrazao)

Related tags: Janssen, Ireland, IDA Ireland

J&J announces the opening of its manufacturing building in Cork, Ireland, which expands the production capacity of the biopharmaceutical supply chain facility.

The work has been ongoing for two years and has seen Janssen, a subsidiary of Johnson & Johnson, invest more than €300m​ ($329m) to increase capacity at the facility by 62,000-square-feet.

The facility is located in Ringaskiddy, Cork, where Janssen holds a 40-hectare site, and the expansion will create 200 full time positions, adding to the approximately 500 people already employed at the site.

Through the expansion, Janssen added a new manufacturing building; expansion of its existing warehouse building, laboratory and administration buildings; modification of other aspects of the site, including car parking and utilities; and expansion of the on-site waste water treatment plant.

The site currently manufactures five commercial products, all of which are monoclonal antibodies: Simponi (golimumab), Stelara (ustekinumab), Sylvant (siltuximab), Darzalex (daratumumab), and Tremfya (guselkumab).

Martin Shanahan, CEO of IDA Ireland, said, “J&J is one of the largest life sciences and R&D investors in Ireland and is part of a thriving biopharma sector in Cork. With a significant investment in expanding Janssen’s manufacturing capacity here in Ringaskiddy, the positive economic spin-off for the South-West region is considerable.”

In addition, Simon Coveney, An Tánaiste and minister for foreign affairs & trade for the Irish government, who was in attendance at the opening ceremony, highlighted the importance of the pharmaceutical and medical products, stating that these constituted 33% of the country’s exports.

During an interview earlier this year​, Shay Power, VP of life sciences at IDA Ireland, told BioPharma-Reporter that over the last seven years, the country had investments of over €1bn, helped by the favorable tax rates offered.

Related topics: Bio Developments, Facilities

Related news

Show more

Related products

show more

Protect your bulk filtration and dispense step

Protect your bulk filtration and dispense step

Parker Bioscience Filtration | 22-Jul-2019 | Data Sheet

Does your process need greater protection when the value of your product is at its highest?

At the bulk filtration and container fill stage,...

Featured eBook: Complex Protein Production

Featured eBook: Complex Protein Production

Catalent Pharma Solutions | 06-Mar-2018 | Technical / White Paper

Download the eBook written by Catalent experts to learn about innovative products and techniques for scale-up of complex biologics, get optimal cell culture...

Related suppliers

Follow us

Products

View more

Webinars